TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9764785
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (800 IU daily) and Vitamin C (1000 mg daily)
Study: 20059603
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents
Study: 16961129
Drug: GliaSite brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GliaSite brachytherapy (60 Gy dose administered to a 1-cm depth after resection)
Study: 1607191
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (EMLA(R))
Study: 25261599
Drug: Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Based Cognitive Therapy (MBCT) with formal home practice of at least 3 days a week
Study: 19940856
Drug: Silver alginate
Normalized name: Care Touch Silver Alginate Wound Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver alginate (Algidex) patches
Study: 18848350
Drug: Consistent bronchodilator
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent bronchodilator response (BDR)
Study: 10813108
Drug: toremifene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: toremifene (40 mg/day; n = 19)
Study: 10813108
Drug: tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamoxifen (20 mg/day; n = 25)
Study: 1640148
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of methylprednisolone acetate plus local anaesthetic
Study: 1640148
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection of local anaesthetic
Study: 31289885
Drug: Alcohol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (low or moderate dosage)
Study: 27067521
Drug: Endostatin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostatin (7.5 mg/m² weekly for 14 days), Paclitaxel (50 mg/m²), Carboplatin (2 mg/mL/min over 30 min) during chemoradiotherapy; followed by Endostatin (7.5 mg/m² for 14 days), Paclitaxel (150 mg/m²), Carboplatin (5 mg/mL/min every 3 weeks for 2 cycles) as consolidation treatment.
Study: 27067521
Drug: Endostatin treatment
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostatin treatment
Study: 12075743
Drug: Alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatment group (A) received docetaxel 100 mg/m2 on days 1 and 43, alternating with cisplatin 100 mg/m2 on day 22 and vinorelbine 30 mg/m2 on days 22, 29, and 36.
Study: 12075743
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (B) received cisplatin 80 mg/m2 on days 1, 22, and 43, and vinorelbine 30 mg/m2 once a week from day 1 to day 57.
Study: 9935086
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid cream twice daily (n=25)
Study: 9935086
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% cream qHS and tretinoin 0.025% cream twice daily (n=25)
Study: 24392599
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin lispro mix 75/25 (LM75/25)
Study: 23567001
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin glargine
Study: 19172535
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg micronized progesterone vaginally three times per day starting in the afternoon of oocyte retrieval until the morning of embryo transfer, in addition to standard hCG luteal-phase support.
Study: 17062301
Drug: AZD3582 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 375 mg
Study: 17062301
Drug: AZD3582 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 750 mg
Study: 17062301
Drug: AZD3582 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 1500 mg
Study: 17062301
Drug: AZD3582 2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 2250 mg
Study: 12920841
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 ropivacaine + 2 mg.L‐1 fentanyl (Group RF)
Study: 12920841
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 2 mg.L‐1 fentanyl (Group BF)
Study: 12920841
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 80 mg.L‐1 morphine (Group BM)
Study: 12920841
Drug: General‐epidural anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General‐epidural anesthesia and patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group EM)
Study: 12920841
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group M)
Study: 10941607
Drug: Psychological support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological support associated with pharmacological treatment (benzodiazepine, gamma‐hydroxybutyric acid)
Study: 3839018
Drug: Efamol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efamol treatment (prostaglandin synthesis precursor)
Study: 29705519
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist anakinra
Study: 16181747
Drug: Pristinamycin (PRI)
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (PRI) 3 g daily for 7 to 10 days
Study: 16181747
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX) 3 g daily for 7 to 10 days
Study: 16181747
Drug: Pristinamycin (PRI)
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (PRI) and Amoxicillin (AMX)
Study: 7720443
Drug: 10-cm stapled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-cm stapled colonic pouch low rectal anastomosis
Study: 30224345
Drug: Panobinostat 40
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 40 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (A arm)
Study: 30224345
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (B arm)
Study: 30224345
Drug: High-dose bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose bicalutamide (historical control)
Study: 27896644
Drug: El Sistema
Normalized name: hydroxypropyl cellulose (type EL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: El Sistema music program (treatment group)
Study: 26655003
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (1.25 mg/0.05 ml) 1 week before surgery
Study: 26655003
Drug: Subconjunctival normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival normal saline (1.25 mg/0.05 ml) 1 week before surgery
Study: 20086314
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg calcium plus 800 IU vitamin D(3)/d (Ca+VD group)
Study: 20086314
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg calcium/d (Ca group)
Study: 16101342
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction intervention with counselling and/or nicotine replacement therapy (NRT)
Study: 12051574
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g b.i.d. dosing of Nitazoxanide
Study: 12051574
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g b.i.d. dosing of Nitazoxanide
Study: 10086859
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied 3 times daily for 4 weeks on one forearm
Study: 2327750
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily for 5 days
Study: 2327750
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily for 5 days
Study: 31540574
Drug: Fabomotizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fabomotizole (10 mg thrice a day)
Study: 28762756
Drug: Intranasal 24
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 24 IU Oxytocin
Study: 23430709
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of patch and oral NRT
Study: 23430709
Drug: Inhalator to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalator to deliver oral NRT
Study: 18076801
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate controlled-released tablet
Study: 18076801
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride sustained-released tablet
Study: 28537501
Drug: Oxycodone controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone controlled release (CR)
Study: 7516641
Drug: Thymopentin +
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin + G‐CSF
Study: 2556079
Drug: Daptomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (1 mg/kg)
Study: 2556079
Drug: Daptomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (2 mg/kg)
Study: 2556079
Drug: Daptomycin and
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin and Amikacin (500 mg)
Study: 2556079
Drug: Daptomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (1 or 2 mg/kg)
Study: 2556079
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg)
Study: 2556079
Drug: Daptomycin and
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin and Amikacin combination
Study: 4154124
Drug: S.A.I.M.R. antivenom
Approvals — FDA: no, EMA: no, PMDA: no
Description: S.A.I.M.R. antivenom (average dose 15.2 ml)
Study: 4154124
Drug: Behringwerke antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behringwerke antivenom (average dose 37.9 ml)
Study: 21563035
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (400 microgram every second hour, total 1600 microgram)
Study: 21563035
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (healthy subjects with no previous use of beta2‐agonists)
Study: 15925911
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg orally daily
Study: 15925911
Drug: Beclomethasone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 400 ug local sprays daily
Study: 9832000
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate vaccine (group 1, n = 69)
Study: 9832000
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide vaccine (group 2, n = 72)
Study: 9832000
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B virus vaccine (group 3, n = 70)
Study: 8130046
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1 and metoclopramide 10 mg
Study: 8130046
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1 and glycopyrronium 5 micrograms kg‐1
Study: 8130046
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1 and hyoscine 5 micrograms kg‐1
Study: 26733277
Drug: Aripiprazole (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (initial dose 5-10 mg per day followed by flexible doses 5-15 mg per day)
Study: 26733277
Drug: Risperidone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day)
Study: 25184356
Drug: Sapropterin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin 200 to 400 mg BID
Study: 20005545
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperoxia and handgrip
Study: 17574795
Drug: Modified therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified therapeutic community (TC) track with psychoeducational seminar, trauma-informed addictions treatment, and case management
Study: 18052566
Drug: Venlafaxine 75-150
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75-150 mg/day
Study: 11262776
Drug: Reconstructive procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reconstructive procedures in surgical treatment of tumors
Study: 9715201
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) 80 mg/400 mg orally three times daily for 10 days
Study: 2648609
Drug: Tear solution
Normalized name: glycerin Ophthalmic Solution [Oasis Tears]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tear solution with polyvinyl alcohol 1.4% m/v preserved with 0.5% m/v chlorobutanol
Study: 2648609
Drug: Tear solutions
Normalized name: glycerin Ophthalmic Solution [Oasis Tears]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tear solutions without chlorobutanol
Study: 15542065
Drug: Platelets from
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets from NIDDM patients in a medium containing 180 mg/dL glucose
Study: 15542065
Drug: Platelets from
Normalized name: Platelet Lysate
DrugBank: Platelet Lysate (DB15869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets from NIDDM patients in a medium containing 90 mg/dL glucose
Study: 8158885
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other antihypertensive treatments excluding ACE inhibitors)
Study: 30232856
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (puncturing specific acupoints with filiform needles, once every other day for 8 weeks)
Study: 30232856
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Study: 25321941
Drug: LipiFlow (automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow (automated thermodynamic treatment)
Study: 22386977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (home-based physical therapy program without vibration training)
Study: 20143872
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg of folic acid daily for 12 weeks
Study: 16573801
Drug: Lansoprazole 90
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 90 mg, 6 mg/h
Study: 16573801
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating tablet 60 mg every 6 h
Study: 16573801
Drug: Lansoprazole 120
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 120 mg, 9 mg/h
Study: 16573801
Drug: Lansoprazole 120
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 120 mg, 6 mg/h
Study: 1558237
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both early active motion and continuous passive motion
Study: 24361229
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with assessment of response at week 12 using anatomic imaging (CT/MRI)
Study: 24361229
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with assessment of response at week 12
Study: 24361229
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with assessment of response at week 12 for ERMS
Study: 24361229
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with assessment of response at week 12 for ARMS
Study: 646600
Drug: Videotape immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotape immediate feedback during rehabilitation sessions (four sessions at weekly intervals)
Study: 31852491
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (Control)
Study: 27883997
Drug: CBT4BN (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4BN (Internet-based manualized CBT group therapy)
Study: 27883997
Drug: CBTF2F (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTF2F (traditional face-to-face group therapy)
Study: 25827507
Drug: Low-dose lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose lithium added to optimized treatment (OPT)
Study: 21029208
Drug: narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: narrow-band UVB monotherapy (PT)
Study: 19899672
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment using empatho-techniques
Study: 8196254
Drug: Digoxin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (35 mg/day)
Study: 8196254
Drug: Captopril (0.31
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.31 mg/day)
Study: 26204531
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell intracoronary transplantation (mean dose of 8.19 ± 4.43 x 10(6) CD34+ cells)
Study: 22049165
Drug: Graded intakes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded intakes of protein (0.1-2.56 g · kg(‐1) · d(‐1))
Study: 22049165
Drug: Current DRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current DRI recommendations for protein (0.76 g · kg(‐1) · d(‐1))
Study: 7957448
Drug: MSP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP (20 mg base of mefloquine/kg body weight)
Study: 7957448
Drug: MSP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP plus primaquine (0.75 mg/kg)
Study: 3069760
Drug: sulconazole nitrate
Normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulconazole nitrate 1% cream applied twice daily for 14 days
Study: 3069760
Drug: miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: miconazole nitrate 2% cream applied twice daily for 14 days
Study: 23187936
Drug: MVC 150
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC 150 mg once daily
Study: 23187936
Drug: TDF/FTC 300/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC 300/200 mg once daily + ATV/r 300/100 mg once daily
Study: 22328095
Drug: Janthinobacterium lividum
Normalized name: Ricinus lividus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janthinobacterium lividum treatment
Study: 16284083
Drug: 17beta-estradiol supplementation
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol supplementation (ES; 2 mg/day)
Study: 15331898
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment (contact and hybrid)
Study: 9497875
Drug: IGF‐I infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I infusion (43.7 pmol/kg/min or 20 micrograms/kg/h)
Study: 9497875
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (3.4 pmol/kg/min or 0.5 mU/kg/min)
Study: 9497875
Drug: IGF‐I infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I infusion
Study: 9497875
Drug: IGF‐I and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I and insulin infusions
Study: 8298916
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch angioplasty (Control)
Study: 29081326
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) exposure therapy, approximately 1 hour
Study: 26635305
Drug: Higher level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher level of amino acids (1.2 g/kg)
Study: 26635305
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid intake (0.8 g/kg)
Study: 25465451
Drug: Oral discussion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral discussion and written handout outlining the risks of otoplasty